Literature DB >> 17605064

[Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].

M A Kern1, K Breuhahn, M Schuchmann, P Schirmacher.   

Abstract

Hepatocellular carcinoma is one of the most prevalent malignancies worldwide and its incidence is increasing. Multimodal strategies directed towards this carcinoma include primary (e.g. immunisation) and secondary (e.g. antiviral therapy) prevention, surgical approaches, novel specific systemic therapies (targeted therapy), and the treatment of comorbidity (cirrhosis). New molecular approaches are currently under development. These tackle several specific targets, with pathology being challenged in many aspects: experimental evaluation, the development of valid tumor-relevant diagnostic tests as well as morphological evaluation in the context of clinical studies, and finally in routine diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17605064     DOI: 10.1007/s00292-007-0890-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   0.973


  122 in total

1.  Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma.

Authors:  O Noguchi; N Enomoto; T Ikeda; F Kobayashi; F Marumo; C Sato
Journal:  J Hepatol       Date:  1996-03       Impact factor: 25.083

2.  Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.

Authors:  H Koga; S Sakisaka; M Ohishi; T Kawaguchi; E Taniguchi; K Sasatomi; M Harada; T Kusaba; M Tanaka; R Kimura; Y Nakashima; O Nakashima; M Kojiro; T Kurohiji; M Sata
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.

Authors:  F Kanai; Y Shiratori; Y Yoshida; H Wakimoto; H Hamada; Y Kanegae; I Saito; H Nakabayashi; T Tamaoki; T Tanaka; K H Lan; N Kato; S Shiina; M Omata
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

4.  Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

Authors:  Michael Höpfner; Andreas P Sutter; Alexander Huether; Detlef Schuppan; Martin Zeitz; Hans Scherübl
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

5.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.

Authors:  Z-H Xian; S-H Zhang; W-M Cong; W-Q Wu; M-C Wu
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

6.  Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.

Authors:  F Eckel; S von Delius; M Mayr; M Dobritz; F Fend; C Hosius; E Schleyer; E Schulte-Frohlinde; R M Schmid; C Lersch
Journal:  Oncology       Date:  2005-11-24       Impact factor: 2.935

7.  Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics.

Authors:  Galia Blum; Aviv Gazit; Alexander Levitzki
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

8.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.

Authors:  Y Murakami; K Hayashi; S Hirohashi; T Sekiya
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

Review 9.  Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  E Tabor
Journal:  J Med Virol       Date:  1994-04       Impact factor: 2.327

10.  Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II.

Authors:  Per Lund; Dominic Schubert; Fataneh Niketeghad; Peter Schirmacher
Journal:  Cancer Lett       Date:  2004-03-31       Impact factor: 8.679

View more
  1 in total

1.  Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma.

Authors:  Hans-Udo Kasper; Uta Drebber; Dirk-Ludger Stippel; Hans-Peter Dienes; Anton Gillessen
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.